Merck launches Vivera in Latin America

MerckMerck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in January 2016, to be followed by several major Latin American markets later in 2016. Vivera provides fast relief from a gastro-intestinal upset by accelerating the natural healing process.

Merck formulated Vivera with B.Aliv®, one of the most researched and most effective probiotics in the world for the treatment of gastro-intestinal upset, which works by regenerating the intestinal flora. The Vivera food supplement comes in a practical and innovative ready-to-use powder sachet, making it an ideal choice for children and adults to use anywhere on-the-go.

Uta Kemmerich-Keil, President and CEO of the Consumer Health business of Merck, commented: "We truly look forward to launching Vivera! Vivera is a fantastic probiotic product which accelerates the healing process after a gastro-intestinal upset and restores the function of the digestive system naturally. I am confident that we have a truly winning proposition for both children and adults, particularly when looking for natural and effective options."

Brand transitions from Biopharma to Consumer Health
Also in Latin America, Merck announced a second wave of brand transfers from its Biopharma business to the Consumer Health business. These start from January 2016 onwards in Colombia, Ecuador and Peru and then in 2017 in Chile. The brands involved in the transfer are Anemidox® / Confer®, a treatment and prevention of iron deficiency related anemia at every stage of life; and Hepabionta®, a liver protector.

Uta Kemmerich-Keil explained, "We have decided to transfer these brands as all of them have great potential for consumerization. Leveraging this approach, we will further develop these brands and thereby generate further growth."

About Merck's Consumer Health Business
Brands of the Consumer Health business, such as Dolo-Neurobion®, Neurobion®, Bion®, Seven Seas®, Nasivin®, and Femibion® are innovative leaders in key markets, backed by science and trusted by consumers worldwide. The Consumer Health business is with over 2,700 employees globally active in over 40 markets. Since 2014, the portfolio comprises of brands with annual total sales of about $ 1 billion. Consumer Health is a business of the Healthcare business sector within the Merck Group with global headquarters in Darmstadt, Germany.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]